Elevation Oncology Announces FDA Fast Track Designation Granted To Seribantumab For Tumor-Agnostic Treatment Of Solid Tumors Harboring NRG1 Gene Fusions
Elevation Oncology Inc (ELEV) - Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-agnostic Treatment of Solid Tumors Harboring Nrg1 Gene Fusions.
